首页> 美国卫生研究院文献>Asia Pacific Allergy >Clinical applications of drug desensitization in the Asia-Pacific region
【2h】

Clinical applications of drug desensitization in the Asia-Pacific region

机译:药物脱敏在亚太地区的临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug desensitization is the induction, within hours to days, of a temporary state of tolerance to a drug which the patient has developed a hypersensitivity reaction to. It may be used for IgE and non-IgE mediated allergic reactions, and certain non-allergic reactions. The indication for desensitization is where no alternative medications are available for the treatment of that condition, and where the benefits of desensitization outweigh the risks. Desensitization is a therapeutic modality for drug allergy (similar to allergen specific immunotherapy for allergic rhinitis and insect venom anaphylaxis). In contrast, the drug provocation test is a diagnostic modality used to confirm or refute the diagnosis of drug allergy. This review discusses the clinical applications of desensitization for the treatment of common infectious, metabolic and cardiovascular diseases, and oncological conditions in the Asia-Pacific region.
机译:药物脱敏是在几小时到几天内诱导对患者产生了超敏反应的药物的暂时耐受状态。它可用于IgE和非IgE介导的过敏反应,以及某些非过敏反应。脱敏的适应症是在没有其他药物可用于治疗该病症的情况下,脱敏的益处大于风险。脱敏是药物过敏的一种治疗方式(类似于过敏性鼻炎和昆虫毒液过敏的过敏原特异性免疫疗法)。相反,药物激发试验是一种用于确认或驳斥药物过敏诊断的诊断方法。这篇综述讨论了脱敏治疗在亚太地区常见的传染,代谢和心血管疾病以及肿瘤状况方面的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号